Boston Scientific Corp. (NYSE:BSX) is adding two blocked artery treatment technologies two its portfolio of vascular treatment devices.
The Natick, Mass.-based medical device giant acquired a re-entry catheter from Israel-based S.I. Therapies Ltd. in November, and, with the pending acquisition of ReVascular Therapeutics Inc., the company is adding an intraluminal chronic total occlusions (CTO) crossing device. Both devices treat peripheral CTOs.